Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 versus salmeterol/fluticasone crossover study in adults with asthma
2016-005164-34Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate, salmeterol + fluticasone in asthma, sponsored by Novartis. Started May 2017; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoatesalmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2016-005164-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005164-34.